Document resource
Background and Importance Oncology treatment requires continuous monitoring and appropriate pharmacotherapeutic management. Telepharmacy offers an innovative alternative to provide pharmaceutical care without the need for travel, which is especially beneficial for immunocompromised patients or those with mobility difficulties.Aim and Objectives To evaluate the effectiveness of personalised telepharmacy in improving treatment adherence and safety, as well as patient acceptance.Material and Methods A telepharmacy program was implemented in the oncology pharmacy consultation. Patients were selected based on criteria such as patient frailty, distance from home to hospital and disease stability. Scheduled calls were conducted to address aspects such as adherence, occurrence of adverse effects, patient education on treatment, and resolution of doubts. Impact indicators such as adherence rates and patient satisfaction were measured. The satisfaction patient degree was evaluated with a numerical result from 1 (minimum satisfaction) to 10 (maximum satisfaction).Results A total of 76 patients were included in the telepharmacy program, 80% were men. The average age was 78 years (standard deviation 5.65). Among them, 65% had prostate cancer, 10% gastric cancer, 10% breast cancer, and 5% had ovarian, renal or lung cancer. The involved drugs were: enzalutamide(25), apalutamide(14), abiraterone (9), abemaciclib(6), capecitabine(6), osimertinib(5), imatinib(5), olaparib(2), pazopanib(2), and sunitinib(2). 152 pharmaceutical interventions were recorded, averaging two per patient. The main interventions were related to education on pathology and oral chemotherapy administration (40%), management of concomitant medications (28%), detection of potential drug interactions (10%), identification of adherence issues (12%), and management of adverse effects (10%). The most frequent adverse events were fatigue (20%), gastrointestinal intolerance (15%), and rash (10%), all managed through telepharmacy follow-up without treatment discontinuation.The leading causes of non-adherence were forgetfulness (45%), underestimation of treatment importance (35%), and gastrointestinal intolerance(20%). Following individualised follow-up, adherence improved from 82% at baseline to 95% at three months. Patient satisfaction was high: 90% reported being ‘very satisfied’ with the accessibility and pharmacist support, achieving a mean satisfaction score of 9.2±0.7.Conclusion and Relevance Personalised telepharmacy in oncology is an effective strategy to optimise pharmaceutical care, improving adherence and treatment safety. Its implementation in clinical practice can contribute to a better quality of life for oncology patients by facilitating access to continuous and specialised follow-up.Conflict of Interest No conflict of interest